- Oct 10, 2018 Jazz Pharmaceuticals Survey Highlights Significant Impact of Excessive Daytime Sleepiness Related to Sleep Apnea
- Sep 11, 2018 Jazz Pharmaceuticals Announces an Informational Webcast for Investors Related to Vyxeos EU Launch
- Aug 29, 2018 Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences
- Aug 27, 2018 Vyxeos® Receives Marketing Authorisation in the European Union for Treatment of Certain Types of High-Risk Acute Myeloid Leukaemia
Data provided by Nasdaq. Minimum 15 minutes delayed.